Oncolytic measles viruses as a multiplexed immune-modulating platform for cancer therapy

Cancer

In numbers
1 m
cancer patients worldwide
1 m
estimated new cancer cases per year
1 m
cancer deaths in 2018

Cancer

In numbers
1 m
cancer patients worldwide
1 m
estimated new cancer cases per year
1 m
cancer deaths in 2018

A multiplexed immune-modulating platform

CanVirex’s Measles Virus Platform – mode of action

» Causing the destruction of cancer cells (=”ONCOLYSIS”)
» Tumor-restricted delivery of immune-modulating transgenes

This leads to a personalized cancer vaccination with the potential to break tumor resistance.

CanVirex’s Measles Virus Platform provides:

Immunogenic oncolysis for cancer vaccination

» Acute inflammation recruits and activates immune cells

» Presentation of tumor antigens to the patient’s immune system

Targeted immune modulation with encoded transgenes

1. Tumor-associated antigens (TAA)

2. Cytokines (e.g. IL-12)

3. Immune checkpoint inhibitors (ICI)

4. Bispecific T cell engagers (BiTE)

 Translational program

Our development involves both, scientific research and clinical testing. CanVirex builds on 15 years of pre-clinical research. An academic pilot study testing an oncolytic measles virus in combination with a checkpoint inhibitory antibody for clinical proof of concept will be initiated end of 2019.

The translational program routinizes consecutive testing of virus constructs, encoding different immune-modulating transgenes.

Accompanying translational research, supported by CanVirex, will give us information on molecular signatures and predictive biomarkers. This will ultimately allow for a personalized therapeutic approach by rational selection of cancer patients.

 Translational program

Our development involves both, scientific research and clinical testing. CanVirex builds on 15 years of pre-clinical research. An academic pilot study testing an oncolytic measles virus in combination with a checkpoint inhibitory antibody for clinical proof of concept will be initiated end of 2019.

The translational program routinizes consecutive testing of virus constructs, encoding different immune-modulating transgenes.

Accompanying translational research, supported by CanVirex, will give us information on molecular signatures and predictive biomarkers. This will ultimately allow for a personalized therapeutic approach by rational selection of cancer patients.

Discovery

Pre-clinical

Clinical

Pilot Study
Investigator-initiated trial (University Hospital Heidelberg) 75%
CanVirex01
45%
CanVirex02
25%
Biomarker program
55%

CanVirex featured in

“Viruses can cause severe, even malignant diseases. However, they can be converted into effective cancer immunotherapy. “

About us

We are a complementary team of leading experts in the field of molecular immunology, clinical oncology, drug development and corporate management

Executive team

Prof. Dr. Dr. Guy Ungerechts

CMO & CSO

Dr. Urs Breitenstein

CFO

Dr. Tobias Speck

SCIENTIFIC PROJECT MANAGER

Dr. Werner Tschollar

Board of Directors

Dr. Werner Tschollar

FOUNDER &
CHAIRMAN OF THE BOARD

Prof. Dr. Dr. Guy Ungerechts

FOUNDER &
BOARD MEMBER

Lic. iur. Sven Hoffmann

BOARD MEMBER

Prof. Dr. Annette Grüters-Kieslich

BOARD MEMBER

Dr. Alan J. Lewis

BOARD MEMBER

Scientific Advisory Board

Prof. Dr. John Bell

SCIENTIFIC DIRECTOR, BIOCANRX, NETWORK OF CENTRES OF EXCELLENCE

Prof. em. Dr. med. Thomas Cerny

CONSULTANT PHYSICIAN AT ST. GALLEN

Prof. Dr. Dirk Jäger

DIRECTOR MEDICAL ONCOLOGY AT NCT HEIDELBERG

Prof. Dr. Dr. Christoph Springfeld

MANAGING PHYSICIAN, MEDICAL ONCOLOGY AT NCT HEIDELBERG

Contact Us

Contact Us

This website is operated by

CanVirex AG
Malzgasse 9
CH – 4052 Basel

Site officer:
Michael Mauch 

Contact us

Drop us a line and we'll get back to you.

Not readable? Change text. captcha txt